TMCnet News
AntriaBio Elects Dr. Barry Sherman to Its Board [Health & Beauty Close - Up](Health & Beauty Close - Up Via Acquire Media NewsEdge) AntriaBio said that it has appointed Barry Sherman, M.D. to its Board of Directors. In its release, the Company said that Dr. Sherman joins its Board as the company prepares for the clinical development of its lead product candidate, AB101, a once-weekly, proprietary, microsphere formulation of insulin with the potential to transform the treatment paradigm in the $10 billion basal insulin market. "Dr. Sherman is a true pioneer of the biotechnology industry. I am thrilled to have him join our Board of Directors and I look forward to leveraging his immeasurable business and scientific expertise," said Nevan Elam, Chairman and Chief Executive Officer. AntriaBio said that Dr. Sherman brings more than 30 years of experience in the biopharmaceutical industry to the Company's Board of Directors. Notably, Dr. Sherman was the first Chief Medical Officer of Genentech in the mid 1990s following his role directing Genentech's clinical research and medical affairs teams in the late 1980s. Dr. Sherman said, "I am excited to join AntriaBio's Board of Directors given the company's unique opportunity to leverage its formulation platform to develop extended release novel therapeutics such as AB101. I look forward to working closely with the management team on AB101 as well as additional potential product pipeline opportunities." Prior to joining Genentech in 1985, Dr. Sherman was Professor of Medicine and Endocrinology at the University of Iowa College of Medicine, where he served as Associate Chairman of the Department of Internal Medicine and Director of the National Institutes of Health- sponsored Clinical Research Center. More Information and Complete Details: www.antriabio.com ((Comments on this story may be sent to [email protected])) (c) 2014 ProQuest Information and Learning Company; All Rights Reserved. |